Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.

April brings news of further biosimilar competition to Lucentis in major European markets.

Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.

Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.